BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
Completed
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1180
- Registration Number
- NCT04516161
- Locations
- 🇺🇸
Bayer Flatiron Xofigo Registry database, Whippany, New Jersey, United States
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects
Phase 1
Completed
- Conditions
- Clinical Pharmacology
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 80
- Registration Number
- NCT04511611
- Locations
- 🇯🇵
Medical Co. LTA Nishikumamoto hospital, Kumamoto, Japan
🇯🇵Fukuoka Mirai Hospital, Fukuoka, Japan
🇯🇵Sumida Hospital, Sumida-ku, Tokyo, Japan
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects
Phase 1
Completed
- Conditions
- Clinical Pharmacology
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 80
- Registration Number
- NCT04511637
- Locations
- 🇯🇵
Fukuoka Mirai Hospital, Fukuoka, Japan
🇯🇵Medical Co. LTA Nishikumamoto hospital, Kumamoto, Japan
🇯🇵Sumida Hospital, Sumida-ku, Tokyo, Japan
Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy ("Dialysis")
Phase 1
Completed
- Conditions
- Prevention of Thromboembolic Events
- Interventions
- Drug: BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5Other: BAY2433334 on dialysis treatment day
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 48
- Registration Number
- NCT04510987
- Locations
- 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 116049
- Registration Number
- NCT04509193
- Locations
- 🇺🇸
US Optum De-Identified EHR data, Whippany, New Jersey, United States
Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 243
- Registration Number
- NCT04507061
- Locations
- 🇫🇮
Turun yliopistollinen keskussairaala, Turku, Finland
🇧🇬MCOMH Preventsia-2000, Stara Zagora, Bulgaria
🇦🇹Zentrum f. klinische Studien Dr. Hanusch GmbH, Wien, Austria
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
Completed
- Conditions
- Renal Insufficiency, Chronic
- Interventions
- Other: No intervention
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 300
- Registration Number
- NCT04498156
- Locations
- 🇨🇦
Many Facilities, Multiple Locations, Canada
A Study to Learn More About Using Dienogest to Treat Endometriosis in Chinese Participants
- First Posted Date
- 2020-08-03
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 968
- Registration Number
- NCT04495855
- Locations
- 🇨🇳
Many locations, Multiple Locations, China
A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)
Phase 1
Completed
- Conditions
- Endometriosis Related PainOveractive BladderDiabetic Neuropathic PainRefractory or Unexplained Chronic Cough
- Interventions
- Drug: [14C]BAY1817080
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT04487431
- Locations
- 🇳🇱
PRAHealthSciences, Groningen, Netherlands
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 206
- Registration Number
- NCT04477707
- Locations
- 🇺🇸
John H Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States
🇺🇸Office of Osvaldo A. Brusco, MD, Corpus Christi, Texas, United States
🇺🇸Joslin Diabetes Center, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath